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Self-assembling protein cages have been exploited as templates for nanoparticle synthesis. The
ferritin molecule, a protein cage present in most living systems, stores excess soluble ferrous iron in
the form of an insoluble ferric complex within its cavity. Magnetic nanocores formed by loading
excess iron within an engineered ferritin from Archaeoglobus fulgidus AfFtn-AA were studied as
a potential magnetic resonance MR imaging contrast agent. The self-assembly characteristics of
the AfFtn-AA were investigated using dynamic light scattering technique and size exclusion
chromatography. Homogeneous size distribution of the assembled nanoparticles was observed using
transmission electron microscopy. The magnetic properties of iron-loaded AfFtn-AA were studied
using vibrating sample magnetometry. Images obtained from a 3.0 T whole-body MRI scanner
showed significant brightening of T1 images and signal loss of T2 images with increased
concentrations of iron-loaded AfFtn-AA. The analysis of the MR image intensities showed
extremely high R2 values 5300 mM−1 s−1 for the iron-loaded AfFtn-AA confirming its potential as
a T2 contrast agent. © 2010 American Vacuum Society. DOI: 10.1116/1.3483216I. INTRODUCTION
Magnetic resonance imaging MRI is a medical imaging
technique used to visualize the detailed internal structure of
parts of the human body. Contrast differences between soft
tissues observed in MR images can be used to diagnose dis-
eased tissues. Contrast agents are often used to enhance con-
trast between soft tissues. For example, during the staging of
liver cancer using MRI, contrast agents are routinely used to
improve the contrast between liver lesions and the surround-
ing tissues, which facilitate lesion detection.1 However, com-
mercially available MRI contrast agents are limited in its
ability to monitor small tissue lesions, and molecular or cel-
lular activities.2 The search for ultrasensitive contrast agents
has become central in MRI research. Beside other metal
complexes, magnetic nanoparticles attract special attention
due to significantly higher relaxivity than those of available
gadolinium-based complexes.3–5 Several nanocarriers, such
as liposomes and microbubbles, have been investigated to
determine their ability to deliver higher amounts of contrast
agent.6–8 For in vivo application, these carrier molecules and
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within physiological system.9 Here we examine a modified
ferritin as a template for synthesizing magnetic nanocore and
the potential application of this metal-protein composite as a
MRI contrast agent. One advantage of utilizing these pro-
teinaceous carriers stems from the protein-associated water
molecules that can contribute to the enhancement of nuclear
relaxation rates.10 In addition, the nanoparticles synthesized
within ferritin cages have a narrow range of particle size
distribution when compared to chemically synthesized
nanoparticles.11
Ferritins are iron storage proteins found in most living
systems; they form roughly spherical cage-like structures
with an internal cavity 8 nm diameter that can be loaded
with a large number of small molecules.12–14 Ferritins con-
vert soluble ferrous salts to a ferric complex, and the latter is
stored within the internal cavity as magnetic nanocores.15,16
T2 contrast enhancements by endogenous ferritin were used
to estimate iron deposition in liver, pancreas, and spleen in
healthy or diseased states.17–21 The surface of the ferritin
molecule can be chemically/genetically modified to impart
novel functionalities including tissue targeting by conjugat-
ing with receptor specific functional groups.13,22,23 Ferritin
encapsulated gadolinium-based contrast agents have also
been reported to have improved R1 relaxivity compared toFA483…/FA48/5/$30.00 ©2010 American Vacuum Society
for A
FA49 Sana et al.: Iron-based ferritin nanocore as a contrast agent FA49the free gadolinium complexes.5,10 On the other hand, human
ferritin iron oxide nanocomposites show relatively low R1
and R2 values.12
In the present study, significantly higher R1 and R2 relax-
ivities were achieved by synthesizing iron based magnetic
nanocores within the cavity of an engineered Archaeoglobus
fulgidus ferritin. The protein cage of wild type A. fulgidus
ferritin AfFtn contains four large pores making it unique
among any ferritin of known structure reported to date.24 In
solutions of low ionic strength, the apo-AfFtn exists as
dimeric species. Increased ionic strength or addition of diva-
lent metal ions leads to the self-assembly of these dimers
into a spherical cage comprised of 24 subunits. In this study,
the lysine150 and arginine151 of AfFtn were replaced by
alanine to modulate the four large pores and the mutant is
referred to as AfFtn-AA. This mutant assembles into cage-
like structure 24-mer at lower ionic strength compared to
AfFtn. Encapsulation of metal ions within the AfFtn-AA cav-
ity facilitates formation of a metallic nanocore Fig. 1. Lon-
gitudinal and transverse relaxivities R1 and R2 of the nano-
composite were studied to evaluate its potential as a MRI
contrast agent. The R1 and R2 values of the samples are
significantly higher compared to those of reported MRI con-
trast agents, thus indicating a new means to enhance R2 re-
laxivity by using this metal-protein nanocomposite.
II. MATERIALS AND METHODS
A. Ferritin
Cloning, expression, and purification of the engineered A.
fulgidus ferritin were carried out following previously de-
scribed method.24 Briefly, the A. fulgidus ferritin gene
AF0834 was cloned into a pET-11a vector and the protein
was genetically engineered by site directed mutagenesis to
alter the amino acids at positions 150 and 151 to alanines
AfFtn-AA. The plasmid was a generous gift from Professor
Imke Schröder at UCLA. The AfFtn-AA was produced in E.
coli BL21DE3 CodonPlus-RIL cells Stratagene, Santa
FIG. 1. Color online Schematic presentation of self-assembly of AfFtn dim
a dimeric species in solutions of low ionic strength and in the absence of diva
a 24-meric protein cage c. Similar self-assembly conditions are observedClara, CA. AfFtn-AA was purified to homogeneity by heat
Biointerphases, Vol. 5, No. 3, September 2010treatment 90 °C for 10 min of cleared cell lysates followed
by hydrophobic interaction chromatography. The purified
protein was stored in 25 mM HEPES with 50 mM NaCl pH
7.5 at 4 °C.
B. Nanocore formation
Iron-based magnetic nanocores were formed following
the method described by Liu et al.25 Freshly prepared ferrous
sulfate solution in 0.1% HCl was slowly added to solutions
of dimeric apo-AfFtn-AA and incubated for 1 h at room
temperature 23 °C and followed by overnight incubation at
4 °C. The iron loading was carried out by adding up to 15
mM Fe2+ to 2.08 M AfFtn-AA in 100 mM HEPES buffer
pH 7.0 containing 50 mM NaCl. Unbound iron was re-
moved by buffer exchange using an Amicon centrifugal filter
device 100 kD MWCO; Millipore, Billerica, MA. Follow-
ing iron loading and buffer exchange, the encapsulated iron
content of the protein was determined by conversion of the
encapsulated ferric complex to the ferrous form and quanti-
fication with bathophenanthroline disulfonic acid, disodium
salt hydrate at 538 nm, as previously described by Bonomi et
al.26 with slight modification. The stoichiometric loading
amount was calculated to be 7200 Fe/24-mer.
C. Characterization of iron-loaded AfFtn-AA
Iron-mediated self-assembly of AfFtn-AA subunits was
studied by monitoring the change of hydrodynamic diameter
upon metal binding using a Zetasizer Nano ZS dynamic light
scattering DLS instrument Malvern Instruments, Worces-
tershire, UK at 25 °C with 5 min equilibration. The molecu-
lar size of apo-AfFtn-AA and iron-loaded AfFtn-AA were
confirmed through size exclusion chromatography SEC us-
ing a Superdex 200 10/300 GL column GE Healthcare,
Buckinghamshire, UK.
TEM was used to verify the self-assembly and to confirm
the dimension of iron-loaded AfFtn-AA molecules. Carbon-
coated parlodion support films mounted on copper grids
d nanocore formation upon addition of Fe2+. AfFtn is observed primarily as
etal ions a. Upon addition of divalent metal ions b, AfFtn subunits form
fFtn-AA.ers an
lent mwere made hydrophilic immediately before use by high-
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loaded AfFtn-AA 0.5 mg/ml; 4800 Fe/24-mer were applied
directly onto grids and allowed to adsorb for 30 s. Grids
were rinsed with 2 drops of double distilled water and
stained with 1% uranyl acetate for 30 s. Specimens were
examined in a T12 electron microscope FEI Tecnai, Hills-
boro, OR at an accelerating voltage of 120 kV.
For magnetic characterization, an aliquot of the iron-
loaded AfFtn-AA 4800 Fe/24-mer was buffer exchanged
with water and lyophilized. The lyophilized iron-loaded
AfFtn-AA was characterized in a 1.5 T 7300 series vibrating
sample magnetometer Lakeshore, Westerville, OH under a
magnetic field strength of up to 1.2 T at room temperature.
D. MR imaging and relaxivity measurement
MRI samples of iron-loaded AfFtn-AA 7000 Fe/24-
mer were prepared with protein concentrations ranging from
0.05 to 1.0 M embedded in a 0.8% agarose matrix in 24-
well tissue culture plates. MR imaging was performed and
MR relaxivities of the samples were calculated to evaluate its
potential as a MRI contrast agent. All samples were imaged
in a 3.0 T whole-body scanner GE Healthcare, Waukesha,
WI using a dedicated knee coil. For the measurement of
longitudinal relaxation times T1, an inversion recovery
spin-echo sequence was used repetition time TR=2200 ms;
echo time TE=9 ms; inversion time TI
=450,500,600,920,800,2000 ms, matrix=512512, slice
thickness=6.0 mm, NEX=1, and field of view=23 cm.
For the measurement of transverse relaxation times T2, a
spin-echo sequence with different echo times was used TR
=1960 ms TE=10,15,20,40,80,120,180,400 ms, matrix
=512512, slice thickness=6.0 mm, NEX=1, and field of
view=23 cm. The T1 and T2 values for each sample were
calculated from mean signal intensity of MR images by us-
ing MATLAB The Mathworks, Natick, MA. For the calcula-
tion of T1 values, a nonlinear fit of the intensity data T1
weighted images to the inversion-recovery signal equation
was performed by using cftool-fitting in customized equa-
tion. The T2 of each sample was calculated by fitting the
intensities of T2 weighted images to a monoexponential de-
cay curve using the same method. Relaxivities R1 and R2
of each sample was derived from the T1 and T2 values at
varying protein concentrations. Gradients of the linear fit ob-
tained by plotting inverse relaxation times 1 /T1 and 1 /T2
against AfFtn-AA concentrations indicate R1 and R2 relax-
ivities, respectively. Images were also acquired using a gra-
dient echo sequence TR=500 ms, TE=6.7 ms, matrix 512
512, slice thickness=4.0 mm, NEX=1, and field of view
=23 cm to assess the relative visual signal at 3.0 T.
III. RESULTS AND DISCUSSION
A. Characterization of iron-loaded AfFtn-AA
Mineralization of dimeric apo-AfFtn-AA with Fe2+ results
in the self-assembly of 24 subunits and the formation of an
iron-protein conjugate. DLS data confirm the self-assembly
of AfFtn-AA subunits. The shift in hydrodynamic diameter
Biointerphases, Vol. 5, No. 3, September 2010from 9.50.9 to 14.51.0 nm corresponds to dimeric spe-
cies in the absence and fully assembled 24-mer in the pres-
ence of iron, respectively Fig. 2a. Assembly of the 24-
mer and the mineralization of the AfFtn-AA is further
confirmed using SEC. The observation of a peak at 310 nm
indicates coelution of ferric iron27,28 with the assembled
AfFtn-AA 24-mer and demonstrates formation of the metal-
protein composite Fig. 2b. Almost 100% of the AfFtn-AA
subunits are assembled into 24-mers in the presence of iron,
while the 20% that form 24-mer in the absence of iron are
due to the presence of sodium chloride in the buffer solution.
Salt-mediated assembly has been previously observed in the
AfFtn.24 Quantification of iron content shows that 7000 Fe
atoms can be encapsulated per 24-meric AfFtn-AA data not
shown. Lower iron loading 4800 Fe/24-mer also results in
the formation of a cage-like structure as revealed in the trans-
mission electron micrograph Fig. 3.
The magnetic properties of iron-loaded AfFtn-AA were
studied by VSM; the magnetization profile is presented in the
hysteresis loop Fig. 4. The curve has a similar shape to the
hysteresis loop of iron-loaded ferritin from the archaeon Py-
rococcus furiosus and engineered human H-chain
ferritin.13,29 The saturated magnetization Ms is 0.435
emu/g, where as retentivity Mr and coercivity Hci of the
composite are 0.052 emu/g and 224 G, respectively.
B. MR imaging and relaxivity
Intensities of the MR images obtained with various con-
centrations of iron-loaded AfFtn-AA were computed to ob-
tain its relaxivity. Higher concentrations of iron-loaded
AfFtn-AA enhance brightness of T1 images and signal loss
of T2 images Fig. 5a. The relative visual signal of MR
images at 3.0 T demonstrates increased contrast at long TEs
data not shown. T1 and T2 values calculated from the sig-
nal intensity decrease sharply with increasing concentra-
tions of iron-loaded AfFtn-AA. The gradients of the linear
FIG. 2. Size determination of apo-AfFtn-AA dashed and assembled 24-mer
AfFtn-AA solid as measured by hydrodynamic diameter in DLS a and
retention volume in SEC b. Correlograms are shown in a inset. The
presence of 310 nm peak at 11 ml indicates coelution of Fe3+ dotted and
the 24-mer AfFtn-AA, as shown in Fig. 2b.fits presented in Fig. 5b indicate the R1 and R2 relaxivities
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ties per iron-loaded AfFtn-AA reach 1200 and
5300 mM−1 s−1, respectively, due to the presence of 7000
Fe atoms in the cavity. The relaxivities of iron-loaded
AfFtn-AA are two orders of magnitude higher than previ-
ously reported R1 and R2 values 8.4 and 93 mM−1 s−1, re-
spectively of human ferritin iron oxide nanocomposites
formed by encapsulating 5000 Fe per cage.12 This observa-
tion suggests that the AfFtn-AA contributes to obtaining sig-
nificantly higher relaxivities in a metal-protein conjugate
when compared to human ferritin iron oxide nanocomposite.
This may be explained by the ability to compartmentalize a
relatively large number of iron atoms and diffusibility of
associated water molecules through ferritin channels, as sug-
gested by Aime et al.10
FIG. 4. Hysteresis loop magnetization vs applied field of iron-loaded
FIG. 3. Transmission electron micrograph of mineralized AfFtn-AA 4800
Fe/24-mer stained with 1% uranyl acetate. Scale bar is 50 nm.AfFtn-AA.
Biointerphases, Vol. 5, No. 3, September 2010The iron-loaded AfFtn-AA molecule also exhibits supe-
rior properties as a T1 contrast agent relative to Gd-loaded
ferritin molecules.10 R1 values for each ferritin-bound Gd3+
complex were 805 mM−1 s−1 under conditions where each
ferritin contained about 10 molecules of the Gd3+ complex.
In contrast, each AfFtn-AA nanocage is capable of encapsu-
lating 7000 Fe atoms and a much higher R1 relaxivity is
observed 1200 mM−1 s−1. In addition, a high R2 /R1
4.5 ratio and a significantly higher R2 value are observed
suggesting the AfFtn-AA nanocore is likely to be suitable as
a T2 contrast agent.
IV. CONCLUSION
The characterization of the iron nanocore synthesized by
encapsulation of Fe atoms within an AfFtn-AA cage con-
firmed its potential as a T2 contrast agent for MR imaging.
R1 and R2 values of iron-loaded AfFtn-AA were much higher
than previously reported human ferritin iron oxide nanocom-
posites. The high iron loading capacity of the AfFtn-AA may
contribute to the observation of the high relaxivity. Another
factor that may also influence the relaxivities is diffusibility
of water molecules through the AfFtn-AA channels. Further
studies need to be conducted in order to better understand
how nanocores within the engineered AfFtn-AA lead to such
a dramatically increased relaxivity. When compared to the
chemical synthesis of nanoparticles, utilization of a ferritin
nanocage allows for precise size control and results in the
synthesis of a highly uniform nanocore having homogeneous
physical characteristics. In addition to serving as a template
for controlled magnetic nanocore formation, the proteina-
ceous nature of ferritin molecules confers additional advan-
tages including the possibility to incorporate functional
groups, which are essential for tissue-specific localization.
Furthermore, by conjugating drug molecules, the ferritin
molecule may serve as a multimodal therapeutic agent that
can simultaneously diagnose and treat diseased tissues.
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